Living With Bone Marrow Failure Diseases - 2022 San Antonio Patient & Family Virtual Conference
In this conference session, Dr. Krisstina Gowin DO discusses best practices when living with bone marrow failure diseases.
patient
The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator
PURPOSE:
Patients who have cancer have leveraged the Internet to gain a better understanding of their disease and connect across geographic boundaries with others facing the same challenges. Online cancer communities have developed into resources that highlight new research and evolving care pathways. Combined with increasing health literacy and social media, they have enabled some patients to become experts in their cancer. This combination of empowerment and expertise describes the new “e-patients.”
ASH 2021 Updates: MDS and Secondary AML
In this webinar, Dr. Elizabeth Griffiths discusses research most relevant to patients reported over the past year on the biology and treatment on MDS and secondary AML. These studies were presented at the American Society of Hematology (ASH) 2021 meeting in Atlanta, GA. Research findings are explained along with the potential impact of this research on understanding and treating MDS and AML. This is an advanced scientific presentation.
Structural Racism is a Mediator of Disparities in Acute Myeloid Leukemia Outcomes
Key Points
Structural racism (SR) assessed by census tract variables accounts for nearly all Black-white and Hispanic-white disparity in AML survival.
Structural Racism is a stronger mediator of survival disparities than molecular features, co-morbidities, healthcare access and treatment.
What's My Doctor Thinking? Treating Secondary AML
Firas El Chaer, MD
El Chaer, Firas
Assistant Professor of Medicine and Medical Director of the Infusion Center
University of Virginia
Being Tired Isn't the Whole Story: Sarah's Post-Transplant Life
Person's Name:
Sarah Anders
Bone Marrow Disease(s):
Content source:
Sabatolimab
Sabatolimab (MBG453) is a novel immuno-myeloid therapy that binds to TIM-3 on immune cells, facilitating antileukemic immune activation and phagocytic killing of leukemic cells. Sabatolimab also binds to TIM-3 on leukemic cells, potentially impeding self-renewal of LSCs via inhibition of TIM3-galectin-9.
Student view: Donor diversity saves lives
Editor's note: Here's an update on Mychaela (see Stories of Hope)
Mychaela Lovelace is a sophomore at Michigan State University majoring in kinesiology in the College of Education, and is a scholar and mentor in the Dow STEM Scholars Program.